ProCE Banner Activity

IMPOWER-22: Monthly Oral Islatravir for PrEP in Cisgender Women

Conference Coverage
Slideset

In a safety analysis of IMPOWER-22, once-monthly islatravir for PrEP was well tolerated among cisgender women without HIV, sexually active with a male partner, and at high-risk for HIV infection. However, consistent with previous islatravir studies, total lymphocyte count decreases were observed.

Released: October 14, 2024

Expiration: October 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner